Biocon has tied up with Mylan for development and commercialisation of generic versions of its three insulin analog products.
According to Biocon’s Chairman and Managing Director, Kiran Mazumdar-Shaw, “Mylan is a natural preferred partner for our portfolio of generic Insulin analogs and this collaboration further strengthens our existing successful partnership.”
Under the terms of this collaboration, Mylan will have the rights to develop and market Biocon’s Glargine (the generic version of Sanofi’s Lantus), Lispro (the generic version of Eli Lilly’s Humalog) and Aspart (the generic version of Novo Nordisk’s NovoLog).
Mylan CEO Heather Bresch said, “This collaboration builds off of our existing successful partnership for generic biologics with Biocon and brings Mylan a portfolio of high-value insulin analog products.”
Mylan and Biocon will share development, capital and certain other costs to bring the products to market. Mylan will have exclusive commercialisation rights in the US, Canada, Australia, New Zealand, the European Union and the European FTA countries through a profit sharing arrangement with Biocon.